UCB And Biogen Report Dapirolizumab Pegol Plus SOC Associated With Higher Response Versus Placebo On Novel TRM-SLE And Greater Sustained Low Disease Activity In Post-Hoc Phase 3 PHOENYCS GO Analyses
Benzinga Newsdesk 1 day ago
News
Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A post-hoc analysis applying TRM-SLE to the DZP Phase 3 PHOENYCS GO
- Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A post-hoc analysis applying TRM-SLE to the DZP Phase 3 PHOENYCS GO data for the first time found greater proportions of patients receiving DZP plus standard of care (SOC) versus placebo plus SOC achieved a clinically meaningful response in at least half or all active organ domains through Week 48
- Sustained low disease activity and remission: In a separate presentation at ACR 2026, post-hoc analyses of PHOENYCS GO showed greater rates of sustained low disease activity and remission across Weeks 40, 44 and 48 with DZP plus SOC versus placebo plus SOC